logo
New STEM camp helps create engineering minded workforce

New STEM camp helps create engineering minded workforce

Yahoo19-07-2025
MORGANTOWN — Claire Drainer was already dominating at rockets as captain of her East Fairmont High rocketry team, so she tried balloons next.
Drainer was one of 17 girls at a new week long summer camp called SpaceTrek, held at the West Virginia University Statler College of Engineering.
'It's amazing, it's a really good opportunity,' Drainer said. 'You get to meet a lot of really nice people and you get to do a lot of things you wouldn't normally get to do.'
SpaceTrek originated at Kentucky's Morehead State University, primarily designed to bring more women into Science, Technology, Engineering and Mathematics. It's made for young women entering grades 9-12 or their first year of college. Professor David Martinelli imported the program from Morehead to WVU, intending to adapt it for Appalachian needs. This is its first year here.
The program itself teaches basic space systems engineering. The girls learn the fundamentals of electronics, wave motion and the electromagnetic spectrum, among other disciplines, as they put together a cricket satellite for launch aboard a balloon.
The balloons climb as high as six kilometers into the atmosphere. After the launch, the team acts as a ground station, by pointing an antenna into the sky and picking up the radio signals the satellite puts out. The girls then use those signals to chart how the radio frequency the satellite is transmitting on changes as it ascends.
State Sen. Mike Oliverio, R-Monongalia County, had to rally after graft funding for the program didn't come through in time. Typically, the program recruits during the fall semester for summer session. Oliverio, along with his wife Melissa, wrote to 54 West Virginia school superintendents and reached out to faculty, principals and STEM clubs. Word reached Drainer's grandmother, who told her granddaughter about it. On Thursday, Drainer's grandmother and her grandfather, Ed Buckner, were on hand to show support.
'I think this is a good opportunity for these kids to be introduced to STEM and be involved in STEM,' Buckner said. 'It's a good opportunity because girls would not be exposed to this kind of environment, with the training they get in the classroom. For instance, soldering and electricy, things like that. There's not an opportunity for them in everyday life to be exposed to that.'
Melissa Oliverio knows first hand the value of programs aimed at young women. In her youth, she attended debate camp at Wake Forest, which sowed the seeds for her to enter law school later. Now as an adult, and despite the fact she wasn't a STEM student, she wanted to make a similar experience available to other young women in rural counties.
'I believe in the value of women learning with other women,' she said. 'This is just a tremendous opportunity, and we just had to try to help get the word out.'
Martinelli said the majority of the girls came from McDowell and Mingo counties. Martinelli said those are some areas that have a disconnect with WVU and the school would love to increase the awareness of higher education there. Having the parents there on the first day of the camp was valuable, and after touring the engineering complex, the parents walked away understanding the value of sending their kids to college.
Three of the girls came from East Fairmont High.
Wes Deadrick, director of NASA's Katherine Johnson IV&V facility in the I-79 High Tech Park in Fairmont, was also present watching the balloon launches.
'You can spend a lot of time in the classroom and lab, but this is really where the rubber hits the road out here,' he said.
Although the NASA facility does more work with software coding and ensuring no mission-ending errors are propagating before a mission launch, and not balloons or atmosphere science, he said programs like SpaceTrek create an important STEM pipeline that gets students excited with the hands-on applications.
'It gives us an engineering-minded workforce, having students that are homegrown that we can pull from the area,' Deadrick said. 'We'd love to hire West Virginians. They're dedicated, hard-working, have some grit and they tend to stay with us.'
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy

Yahoo

time19 minutes ago

  • Yahoo

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy

We recently compiled a list of Denali Therapeutics Inc. stands sixth on our list among the best future stocks. Denali Therapeutics Inc. (NASDAQ:DNLI) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, focused on developing therapies for neurodegenerative and lysosomal storage disorders. Its proprietary TransportVehicle (TV) technology enables the delivery of biologics across the blood-brain barrier, targeting neurological symptoms often left untreated by conventional therapies. In July 2025, the company achieved a major milestone as the FDA accepted and granted Priority Review for its Biologics License Application (BLA) for tividenofusp alfa, a novel enzyme replacement therapy for Hunter syndrome (MPS II). This designation highlights the urgent medical need and sets a PDUFA decision date of January 5, 2026, opening the door for potential approval and launch by early 2026. Tividenofusp alfa is a first-in-class brain-penetrant enzyme therapy designed to overcome a key limitation of current treatments, which do not reach the brain and fail to address neurological symptoms. In clinical trials, Denali Therapeutics Inc. (NASDAQ:DNLI)'s therapy demonstrated effective delivery of the missing enzyme to the central nervous system, showing promise for addressing both somatic and neurological aspects of Hunter syndrome. A scientist in a labcoat inspecting a microscope focusing on a microorganism related to the biopharmaceutical company's therapies. If approved, this therapy would not only offer new hope for patients with Hunter syndrome but also validate the corporation's TV platform, accelerating the development of additional treatments for other disorders like Sanfilippo syndrome (DNL126) and other central nervous system diseases. The milestone marks a transformative moment for Denali Therapeutics Inc. (NASDAQ:DNLI), potentially expanding its leadership in next-generation rare disease therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Clouds force last-minute delay for astronaut launch to the International Space Station
Clouds force last-minute delay for astronaut launch to the International Space Station

Associated Press

time20 minutes ago

  • Associated Press

Clouds force last-minute delay for astronaut launch to the International Space Station

CAPE CANAVERAL, Fla. (AP) — Thick clouds prompted SpaceX to call off Thursday's planned launch of four astronauts to the International Space Station for NASA. The countdown was halted at the one-minute, 7-second mark. SpaceX's next launch attempt from Kennedy Space Center is Friday, although the weather forecast is less favorable. The U.S., Japanese and Russian crew will spend at least six months at the space station, replacing colleagues launched in March as the fill-ins for NASA's two stuck astronauts. Transportation Secretary Sean Duffy, who's temporarily leading NASA, was at Kennedy Space Center for the launch attempt. The morning started out with ideal weather, but the wind picked up and the clouds rolled in. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

Yahoo

timean hour ago

  • Yahoo

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

We recently compiled a list of ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body's natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy. In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients. Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia's health system will bring the Cancer BioShield platform to the Middle East. The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles. A laboratory technician using high tech equipment to sequence cancer genomics. By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store